Background Numerous studies have tried to determine the association between continuity
and outcomes. Studies doing so must actually measure continuity. If continuity and …

Oral anticoagulation is pivotal in the management of thromboembolic risk in non-valvular
atrial fibrillation (NVAF) patients. Effective anticoagulation is important to avoid major …

Background Effectiveness and safety of warfarin is associated with the time in therapeutic
range (TTR) with an international normalised ratio (INR) of 2· 0–3· 0. In the Randomised …

Aims The objective of this paper is to systematically review the literature on drug–drug
interactions with warfarin, with a focus on patient‐important clinical outcomes. Methods …

The stroke rate in atrial fibrillation is 4.5% per year, with death or permanent disability in over
half. The risk of stroke varies from under 1% to over 20% per year, related to the risk factors …

Thromboembolism is a severe complication in atrial fibrillation. This overview presents
thromboembolic disease as a single entity, ranging from stroke through mesenteric ischemia …

Background Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K
antagonists (VKAs) to prevent thromboembolic events, but their use increases the risk of …

Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for
decades. However, with the US Food and Drug Administration approval of new oral …

Achieving therapeutic anticoagulation with warfarin is complicated by substantial inter-
patient and intra-patient variability with numerous factors known to influence dose …

Vitamin K antagonists (VKAs) are effective oral anticoagulants that are titrated to a narrow
therapeutic international normalized ratio (INR) range. We reviewed published literature …